1.99
price down icon0.50%   -0.01
pre-market  Pre-market:  2.41   0.42   +21.11%
loading
Acrivon Therapeutics Inc stock is traded at $1.99, with a volume of 203.72K. It is down -0.50% in the last 24 hours and down -64.53% over the past month. Acrivon Therapeutics Inc is a clinical-stage biopharmaceutical company developing oncology medicines that the Firm matches to patients whose tumors are predicted to be sensitive to each specific medicine by utilizing its proteomics-based patient responder identification platform. The company's pipeline includes the Phase 2 lead program, ACR-368, referred to as prexasertib, a targeted oncology asset, as well as preclinical stage pipeline programs targeting critical nodes in the DNA Damage Response and cell cycle regulation pathways, including WEE1, a protein kinase, and PKMYT1, a closely related protein serine/threonine kinase.
See More
Previous Close:
$2.00
Open:
$2
24h Volume:
203.72K
Relative Volume:
1.20
Market Cap:
$56.75M
Revenue:
-
Net Income/Loss:
$-69.00M
P/E Ratio:
-0.7158
EPS:
-2.78
Net Cash Flow:
$-55.26M
1W Performance:
+9.94%
1M Performance:
-64.53%
6M Performance:
-75.22%
1Y Performance:
-79.05%
1-Day Range:
Value
$1.86
$2.00
1-Week Range:
Value
$1.7606
$2.12
52-Week Range:
Value
$1.30
$10.29

Acrivon Therapeutics Inc Stock (ACRV) Company Profile

Name
Name
Acrivon Therapeutics Inc
Name
Phone
617-207-8979
Name
Address
480 ARSENAL WAY, SUITE 100, WATERTOWN
Name
Employee
78
Name
Twitter
Name
Next Earnings Date
2025-03-26
Name
Latest SEC Filings
Name
ACRV's Discussions on Twitter

Compare ACRV with other stocks

Stocks Price Market Cap Revenue Net Income Cash Flow EPS
Biotechnology icon
ACRV
Acrivon Therapeutics Inc
1.99 56.75M 0 -69.00M -55.26M -2.78
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
492.47 125.74B 11.02B -535.60M -978.00M -2.20
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
599.76 61.57B 14.20B 4.41B 3.54B 38.28
Biotechnology icon
ARGX
Argen X Se Adr
600.51 36.40B 2.19B 833.04M -1.28B 12.71
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
242.61 30.36B 2.25B -278.16M -42.59M -2.17
Biotechnology icon
ONC
Beigene Ltd Adr
256.16 24.89B 3.81B -644.79M -669.77M -6.24

Acrivon Therapeutics Inc Stock (ACRV) Upgrades & Downgrades

Date Action Analyst Rating Change
Jan-31-25 Initiated KeyBanc Capital Markets Overweight
Sep-16-24 Upgrade Ladenburg Thalmann Neutral → Buy
Apr-29-24 Downgrade Ladenburg Thalmann Buy → Neutral
Mar-01-24 Initiated JMP Securities Mkt Outperform
Dec-15-23 Resumed Jefferies Buy
Oct-05-23 Initiated Maxim Group Buy
Jun-02-23 Initiated Oppenheimer Outperform
May-08-23 Initiated BMO Capital Markets Outperform
Apr-27-23 Initiated Ladenburg Thalmann Buy
Apr-20-23 Initiated H.C. Wainwright Buy
Dec-12-22 Initiated Cowen Outperform
Dec-12-22 Initiated Jefferies Buy
Dec-12-22 Initiated Piper Sandler Overweight
View All

Acrivon Therapeutics Inc Stock (ACRV) Latest News

pulisher
Apr 23, 2025

(ACRV) On The My Stocks Page - news.stocktradersdaily.com

Apr 23, 2025
pulisher
Apr 22, 2025

April 2025's Standout Penny Stocks - simplywall.st

Apr 22, 2025
pulisher
Apr 20, 2025

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Short Interest Up 21.4% in March - Defense World

Apr 20, 2025
pulisher
Apr 14, 2025

Down -70.22% in 4 Weeks, Here's Why You Should You Buy the Dip in Acrivon Therapeutics, Inc. (ACRV) - NewsBreak: Local News & Alerts

Apr 14, 2025
pulisher
Apr 08, 2025

Acrivon Therapeutics' SWOT analysis: oncology innovator's stock faces pivotal moment By Investing.com - Investing.com South Africa

Apr 08, 2025
pulisher
Apr 08, 2025

Acrivon Therapeutics’ SWOT analysis: oncology innovator’s stock faces pivotal moment - Investing.com India

Apr 08, 2025
pulisher
Apr 08, 2025

Acrivon Therapeutics' SWOT analysis: oncology innovator's stock faces pivotal moment - Investing.com

Apr 08, 2025
pulisher
Apr 08, 2025

Acrivon Therapeutics, Inc. (NASDAQ:ACRV) Receives $23.17 Average Price Target from Analysts - Defense World

Apr 08, 2025
pulisher
Apr 07, 2025

Acrivon Therapeutics Reports Progress in Cancer Drug Development - TipRanks

Apr 07, 2025
pulisher
Apr 07, 2025

Acrivon Therapeutics Appoints Mansoor Raza Mirza, M.D., as Chief Medical Officer - citybiz

Apr 07, 2025
pulisher
Apr 07, 2025

Acrivon appoints new chief medical officer to advance cancer trials By Investing.com - Investing.com South Africa

Apr 07, 2025
pulisher
Apr 07, 2025

Acrivon Therapeutics Appoints Mansoor Mirza as Medical Chief - marketscreener.com

Apr 07, 2025
pulisher
Apr 07, 2025

Acrivon appoints new chief medical officer to advance cancer trials - Investing.com

Apr 07, 2025
pulisher
Apr 07, 2025

Acrivon Therapeutics Appoints New Chief Medical Officer - TipRanks

Apr 07, 2025
pulisher
Apr 07, 2025

Acrivon Therapeutics Appoints World-Renowned Oncology Key - GlobeNewswire

Apr 07, 2025
pulisher
Mar 29, 2025

Q1 Earnings Forecast for ACRV Issued By HC Wainwright - Defense World

Mar 29, 2025
pulisher
Mar 29, 2025

Acrivon Therapeutics (NASDAQ:ACRV) and Astellas Pharma (OTCMKTS:ALPMY) Head to Head Contrast - Defense World

Mar 29, 2025
pulisher
Mar 28, 2025

H.C. Wainwright maintains Acrivon stock Buy rating, $19 target By Investing.com - Investing.com Australia

Mar 28, 2025
pulisher
Mar 28, 2025

Acrivon Therapeutics, Inc. (ACRV) Upgraded to Buy: Here's What You Should Know - MSN

Mar 28, 2025
pulisher
Mar 28, 2025

Acrivon Therapeutics price target lowered to $10 from $18 at Oppenheimer - TipRanks

Mar 28, 2025
pulisher
Mar 28, 2025

Here's Why Acrivon Therapeutics, Inc. (ACRV) is Poised for a Turnaround After Losing -52.81% in 4 Weeks - Yahoo Finance

Mar 28, 2025
pulisher
Mar 28, 2025

H.C. Wainwright maintains Acrivon stock Buy rating, $19 target - Investing.com

Mar 28, 2025
pulisher
Mar 28, 2025

HC Wainwright Has Lowered Expectations for Acrivon Therapeutics (NASDAQ:ACRV) Stock Price - Defense World

Mar 28, 2025
pulisher
Mar 28, 2025

FY2029 Earnings Estimate for ACRV Issued By HC Wainwright - Defense World

Mar 28, 2025
pulisher
Mar 28, 2025

Cantor Fitzgerald Reaffirms “Overweight” Rating for Acrivon Therapeutics (NASDAQ:ACRV) - Defense World

Mar 28, 2025
pulisher
Mar 27, 2025

Acrivon Therapeutics reports Q4 EPS (60c), consensus (70c) - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Acrivon Therapeutics Provides Program Updates and Fourth Quarter and Full Year 2024 Financial Results - GlobeNewswire

Mar 27, 2025
pulisher
Mar 27, 2025

Breakthrough: Acrivon's Cancer Drug Shows 35% Response Rate in Hard-to-Treat Endometrial Cancer - Stock Titan

Mar 27, 2025
pulisher
Mar 27, 2025

Acrivon Therapeutics Reports 2024 Financial Results and Progress - TipRanks

Mar 27, 2025
pulisher
Mar 27, 2025

Long Term Trading Analysis for (ACRV) - news.stocktradersdaily.com

Mar 27, 2025
pulisher
Mar 27, 2025

Acrivon narrows focus for ACR-368 in endometrial cancer - BioWorld MedTech

Mar 27, 2025
pulisher
Mar 27, 2025

JMP maintains Acrivon stock with $17 target following update By Investing.com - Investing.com Australia

Mar 27, 2025
pulisher
Mar 26, 2025

Acrivon Therapeutics stock target cut to $19 by H.C. Wainwright - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

12 Health Care Stocks Moving In Wednesday's Intraday Session - Benzinga

Mar 26, 2025
pulisher
Mar 26, 2025

Crude Oil Gains Over 1%; Cintas Shares Jump After Q3 Earnings - Benzinga

Mar 26, 2025
pulisher
Mar 26, 2025

Nasdaq Down 1%; Dollar Tree To Sell Family Dollar Business For $1 Billion - Benzinga

Mar 26, 2025
pulisher
Mar 26, 2025

Humacyte to raise $50M; Acrivon to focus on prexasertib in endometrial cancer - Endpoints News

Mar 26, 2025
pulisher
Mar 26, 2025

Cantor Fitzgerald maintains Overweight on Acrivon stock By Investing.com - Investing.com South Africa

Mar 26, 2025
pulisher
Mar 26, 2025

Cantor Fitzgerald maintains Overweight on Acrivon stock - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

JMP maintains Acrivon stock with $17 target following update - Investing.com

Mar 26, 2025
pulisher
Mar 26, 2025

Wednesday Sector Laggards: Biotechnology, Semiconductors - Nasdaq

Mar 26, 2025
pulisher
Mar 25, 2025

Acrivon Therapeutics’ SWOT analysis: innovative oncology firm’s stock potential By Investing.com - Investing.com Australia

Mar 25, 2025
pulisher
Mar 25, 2025

Citizens JMP reiterates Acrivon stock with $17 target By Investing.com - Investing.com South Africa

Mar 25, 2025
pulisher
Mar 24, 2025

Acrivon Therapeutics’ SWOT analysis: innovative oncology firm’s stock potential - Investing.com

Mar 24, 2025
pulisher
Mar 24, 2025

Citizens JMP reiterates Acrivon stock with $17 target - Investing.com

Mar 24, 2025

Acrivon Therapeutics Inc Stock (ACRV) Financials Data

Revenue

loading

Net Income

loading

Cash Flow

loading

EPS

loading
$20.54
price up icon 2.04%
$68.96
price down icon 2.60%
$32.03
price up icon 1.07%
$36.70
price up icon 10.44%
$120.54
price up icon 4.97%
biotechnology ONC
$256.16
price up icon 2.82%
Cap:     |  Volume (24h):